Literature DB >> 32232543

[Hybrid imaging of the abdomen and pelvis. German version].

Krista Elise Suarez-Weiss1, Alexander Herold2, Debra Gervais1, Edwin Palmer1, Bárbara Amorim3, Joseph D King1, Li Weier1, Tajmir Shahein1, Hanna Bernstine4, Liran Domachevsk4, Lina Garcia Cañamaque5, Lale Umutlu, Ken Herrmann, David Groshar4, Onofrio A Catalano6,7.   

Abstract

Accurate imaging is crucial for lesion detection in abdominal organs, for the noninvasive characterization of focal and diffuse abnormalities, and for surgical planning. To accomplish these tasks, several imaging modalities such as multidetector computer tomography (MDCT), magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) are used for abdominal imaging, providing important morphological, functional or metabolic information. More recently, PET/MRI has been gaining attention due to the possibility of combining high-resolution imaging with metabolic imaging. PET/MRI is a novel hybrid imaging technology that in the near future might play a pivotal role in the clinical management of oncologic and inflammatory abdominopelvic diseases. Despite the still limited number of published clinical studies, PET/MRI has been proven to be at least equivalent to PET/CT and to stand-alone MRI in a variety of oncologic disease. Moreover, in selected and focused clinical studies, it has been proven to outperform current standard of care imaging, for example, in evaluating cholangiocarcinomas, liver metastases, untreated and treated rectal cancer. This has also had an impact on therapeutic management in some studies. Therefore in some institutions, including those of the authors, PET/MRI is becoming the new standard imaging modality in staging treatment-naïve intrahepatic mass-forming cholangiocarcinomas and prior to complicated hepatic surgery.

Entities:  

Keywords:  Cholangiocarcinoma; Liver; Positron emission tomography/magnetic resonance imaging; Rectum; Staging

Year:  2020        PMID: 32232543     DOI: 10.1007/s00117-020-00660-y

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  73 in total

1.  Selection of patients for resection of hepatic colorectal metastases: expert consensus statement.

Authors:  Chusilp Charnsangavej; Bryan Clary; Yuman Fong; Axel Grothey; Timothy M Pawlik; Michael A Choti
Journal:  Ann Surg Oncol       Date:  2006-09-01       Impact factor: 5.344

2.  Colorectal cancer staging: comparison of whole-body PET/CT and PET/MR.

Authors:  Onofrio A Catalano; Artur M Coutinho; Dushyant V Sahani; Mark G Vangel; Michael S Gee; Peter F Hahn; Thomas Witzel; Andrea Soricelli; Marco Salvatore; Ciprian Catana; Umar Mahmood; Bruce R Rosen; Debra Gervais
Journal:  Abdom Radiol (NY)       Date:  2017-04

Review 3.  Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma.

Authors:  Gregory D Leonard; Baruch Brenner; Nancy E Kemeny
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

Review 4.  The current landscape of locally advanced rectal cancer.

Authors:  Mebea Aklilu; Cathy Eng
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

Review 5.  Retroperitoneal fibrosis.

Authors:  Augusto Vaglio; Carlo Salvarani; Carlo Buzio
Journal:  Lancet       Date:  2006-01-21       Impact factor: 79.321

6.  PET/MRI for the evaluation of patients with lymphoma: initial observations.

Authors:  Laura Heacock; Joseph Weissbrot; Roy Raad; Naomi Campbell; Kent P Friedman; Fabio Ponzo; Hersh Chandarana
Journal:  AJR Am J Roentgenol       Date:  2015-04       Impact factor: 3.959

7.  Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence.

Authors:  Punit Sharma; Rakesh Kumar; Harmandeep Singh; Sunil Jeph; Daya Nand Sharma; Chandrasekhar Bal; Arun Malhotra
Journal:  Clin Nucl Med       Date:  2012-07       Impact factor: 7.794

8.  Non-small cell lung cancer: dual-modality PET/CT in preoperative staging.

Authors:  Gerald Antoch; Jörg Stattaus; Andre T Nemat; Simone Marnitz; Thomas Beyer; Hilmar Kuehl; Andreas Bockisch; Jörg F Debatin; Lutz S Freudenberg
Journal:  Radiology       Date:  2003-09-25       Impact factor: 11.105

9.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

10.  Diagnostic accuracy of (18)F-2-deoxy-fluoro-D-glucose positron emission tomography for pN2 lymph nodes in patients with lung cancer.

Authors:  Yoshiyuki Ozawa; Masaki Hara; Keita Sakurai; Motoo Nakagawa; Tsuneo Tamaki; Masami Nishio; Yuta Shibamoto
Journal:  Acta Radiol       Date:  2010-03       Impact factor: 1.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.